Abbott To Highlight Expanding Cancer Diagnostic Portfolio And Clinical Evidence At Digestive Disease Week (DDW) 2026

New data from multiple abstracts across colorectal, liver and esophageal cancersdemonstrate a new standard in cancer screening, and commitment to improving patient outcomes

ABBOTT PARK, Ill., April 30, 2026 — Abbott, a leader in cancer screening and diagnostic tests, today announced it will present six abstracts highlighting strong disease detection and practice-changing evidence during Digestive Disease Week (DDW) 2026, May 2-5, 2026, in Chicago. The data reflect the continued growth of Abbott's cancer diagnostics portfolio and its focus on addressing critical gaps in cancer detection for patients and clinicians. DDW is the premier meeting for professionals working in gastroenterology, hepatology, GI endoscopy, and gastrointestinal surgery. DDW will make abstracts available on its website on May 2, 2026.

Six additional topics were also accepted for theWorld Endoscopy Organization Colorectal Cancer Screening Committee meeting on May 1, including data on CRC mortality reduction, follow-up colonoscopy adherence, and comparative performance of multitarget stool DNA testing.

"These data underscore the strength of Abbott's cancer diagnostics portfolio," said Paul Limburg, M.D., chief medical officer, screening, Abbott's cancer diagnostics business. "New data highlighting the potential of emerging liver and esophageal tests support progress toward our goal of reducing the cancer burden for patients and our healthcare system. In addition, CRC screening data at DDW reinforce the strength of the Cologuard test in driving better outcomes and getting more people screened."

The abstracts at DDW are as follows:

Saturday, May 2, 2026, from 10 - 10:15 a.m. Central Time

- Positive and negative predictive value of a non-endoscopic molecular Barrett's esophagus detection test in screening eligible adults: final results from a large multicenter population based clinical trial (Oral lecture).

Sunday, May 3, 2026, from 2:15 - 3:15 p.m. Central Time

- Performance of a multi-target blood test and ultrasound for detection of hepatocellular carcinoma across clinical subgroups (Oral lecture).

Monday, May 4, 2026, from 3:17 PM - 3:24 p.m. Central Time

- Correlation between forceps biopsy histology and wats brush based Barrett's esophagus and dysplasia diagnosis in a large community based screening trial (Oral lecture).

Tuesday, May 5, 2026, from 12:30 - 1:30 p.m. Central Time

- Detection of sessile serrated lesions and advanced precancerous neoplasia: screening comparative performance of next-generation multitarget stool DNA (mt-sDNA) versus FIT.
- Estimated payments for follow-up colonoscopy after a positive noninvasive screening test result: insights from a national claims dataset.
- Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.

About the Cologuard and Cologuard Plus tests

Developed in collaboration with Mayo Clinic, the Cologuard® and Cologuard Plus® tests are first-line, noninvasive colorectal cancer (CRC) screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation or time off, and return the kit to the lab for results. It is also the only noninvasive molecular CRC screening test recommended by USPSTF (2021), and both Cologuard and Cologuard Plus are included in HEDIS® quality measures and the ACS guidelines (2025).

Building on this success, the FDA-approved Cologuard Plus test features novel biomarkers, improved laboratory processes, and enhanced sample stability. Through high performance, the Cologuard Plus test is designed to reduce the likelihood of false positives, helping to minimize unnecessary follow-up colonoscopies. Further, Cologuard Plus is the only USPSTF-recommended test that is FDA approved for both the detection of cancer and precancer. Both tests demonstrate Abbott's commitment to improving CRC screening access and outcomes.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

For further information: Abbott Media: Lindsey Dickinson, (608) 690-0383, Abbott Financial: Michael Comilla, (224) 668-1872